Abstract
The ability of bromocriptine (BRC), a dopamine D-2 receptor agonist, to induce climbing behaviour was studied in mice. BRC (2–32 mg/kg IP) evoked climbing behaviour. The maximum effect was obtained with 8 mg/kg, while higher doses of BRC (16 and 32 mg/kg) were less effective. Climbing began about 2 h after injection and was most marked 5 h after bromocriptine administration. Pretreatment of animals with the dopamine antagonist pimozide (0.5 mg/kg IP) decreased BRC-induced climbing. Sulpiride (0.25–1.25 mg/kg IP), a potent D-2 antagonist and/or SCH 23390 (0.025 and 0.05 mg/kg SC), a D-1 receptor antagonist, also decreased the response. Furthermore, the climbing behaviour induced by BRC was abolished by pretreatment with reserpine plus alpha-methyl-p-tyrosine (AMPT). Concomitant administration of apomorphine (APO) and BRC potentiated the effect of APO on climbing. Concomitant injection of BRC and SKF 38393 (SKF, D-1 agonist) reduced the effect of SKF on climbing, while administration of BRC 4 h before SKF potentiated the effect of both drugs. It is suggested that BRC induces climbing through D-1 and/or D-2 dopamine receptors.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Altar CA, O'Neil S, Walter RJ, Marshall JF (1985) Brain dopamine and serotonin receptor sites revealed by digital substraction autoradiography. Science 228:597–600
Andén NE, Rubenson A, Fuxe K, Hökfelt T (1967) Evidence for dopamine receptor stimulation by apomorphine. J Pharm Pharmacol 19:627–629
Bergh T, Nillius SJ, Wide L (1978) Bromocriptine treatment of 42 hyperprolactinaemic women with secondary amenorrhoea. Acta Endocrinol (Copenh) 88:435–451
Costall B, Eniojukan JF, Naylor RJ (1982) Spontanous climbing behaviour of mice, its measurement and dopaminergic involvement. Eur J Pharmacol 85:125–132
Costall B, Eniojukan JF, Naylor RJ (1983) The mesolimbic nucleus accumbens is critically involved with the mediation of the motor inhibitory and facilitatory effects of dopamine agonists on mouse spontanous climbing behaviour. Eur J Pharmacol 96:201–210
Di Chiara G, Porceddu GML, Vargui L, Angiolas A, Gessa GL (1976) Evidence for dopamine receptors mediating sedation in the mouse brain. Nature 264:564–567
Fuxe K, Fredholm BB, Agnati LF, Ögren SO, Everitt BJ, Jonsson G, Gustafsson JA (1978) Interaction of ergot drugs with central monoamine systems — evidence for a high potential in the treatment of mental and neurological disorders. Pharmacology 16:99–134
Gianutsos G, Palmeri JL (1983) Effects of three dopamine agonists on cage climbing behaviour. Psychopharmacology 79:329–331
Gonzalez-Lima F, Stiehl WL, Medina R (1984) Long-lasting behavioural effects of bromocriptine in cats. Eur J Pharmacol 102:279–287
Hyttel J (1984) Functional evidence for selective dopamine D-1 receptor blockade by SCH 23390. Neuropharmacology 23:1395–1401
Jackson DM, Hashizume M (1986) Bromocriptine induces marked locomotor stimulation in dopamine-depleted mice when D-1 dopamine receptors are stimulated with SKF 38393. Psychopharmacology 90:147–149
Jackson DM, Jenkins OF, Ross SB (1988) The motor effects of bromocriptine — a review. Psychopharmacology 95:433–446
Jenkins OF, Jackson DM (1985) Bromocriptine potentiates the behavioural effects of directly and indirectly acting dopamine receptor agonists in mice. Naunyn Schmiedebergs Arch Pharmacol 331:7–11
Kebabian JW, Calne DB (1979) Multiple receptors for dopamine. Nature (Lond) 227:93–96
Lieberman A, Zolfaghari M, Boal D, Hassan H, Vogel B, Battista H, Fuxe K, Goldstein M (1976) The antiparkinson efficacy of bromocriptine. Neurology 26:405–409
Marcais H, Protais P, Costentin J, Schwartz JC (1978) A gradual score to evaluate the climbing behaviour elicited by apomorphine in mice. Psychopharmacology 56:233–234
Martres MP, Bouthenet ML, Sales N, Sokoloff P, Schwartz JC (1985) Widespread distribution of brain dopamine receptors evidenced with (135I) iodosulpiride, a highly selective ligand. Science 228:752–755
Moore NA, Axton MS (1988) Production of climbing behaviour in mice requires both D1 and D2 receptor activation. Psychopharmacology 94:263–266
Nielsen M, Klimek V, Hyttel J (1984) Distinct target size of dopamine D-1 and D-2 receptors in rat striatum. Life Sci 35:325–332
Protais P, Dubuc I, Costentin J (1983) Pharmacological characteristics of dopamine receptors involved in the dual effect of dopamine agonists on yawning behaviour in rats. Eur J Pharmacol 94:271–280
Schultz W (1982) Depletion of dopamine in the striatum as an experimental model of parkinsonism: direct effects and adaptive mechanisms. Prog Neurobiol 18:121–166
Silbergeld EK, Pfeifer RF (1977) Differential effects of three dopamine agonists. Apomorphine, bromocriptine and lergotrile. J Neurochem 28:1323–1326
Stoof JC, Kebabian JW (1984) Two dopamine receptors: biochemistry, physiology and pharmacology. Life Sci 35:2281–2296
Titeler M, Seeman P (1979) Brain dopamine receptors. In: International Symposium on Ergot Alkaloids, New York, pp 6–7
Ungerstedt U, Arbutnott G (1970) Quantitative recording of rotational behaviour in rats after 6-hydroxydopamine lesions of the nigrostriatal dopamine system. Brain Res 24:485–493
Van Ree JM, Wolternik G (1981) Injection of low doses of apomorphine into the nucleus accumbens of rats reduces locomotor activity. Eur J Pharmacol 72:107–111
Vasse M, Chagraoui A, Protais P (1988) Climbing and stereotyped behaviour in mice require the stimulation of D-1 dopamine receptors. Eur J Pharmacol 148:221–229
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Zarrindast, MR., Shahed-Dirin, K. Bromocriptine induces climbing behaviour: possible D-1 or D-2 dopamine receptor involvement. Psychopharmacology 100, 275–280 (1990). https://doi.org/10.1007/BF02244418
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF02244418